Non-alcoholic fatty liver disease and diabetes: from physiopathological interplay to diagnosis and treatment
- PMID: 25024596
- PMCID: PMC4093691
- DOI: 10.3748/wjg.v20.i26.8377
Non-alcoholic fatty liver disease and diabetes: from physiopathological interplay to diagnosis and treatment
Abstract
Non-alcoholic fatty liver disease (NAFLD) is highly prevalent in patients with diabetes mellitus and increasing evidence suggests that patients with type 2 diabetes are at a particularly high risk for developing the progressive forms of NAFLD, non-alcoholic steatohepatitis and associated advanced liver fibrosis. Moreover, diabetes is an independent risk factor for NAFLD progression, and for hepatocellular carcinoma development and liver-related mortality in prospective studies. Notwithstanding, patients with NAFLD have an elevated prevalence of prediabetes. Recent studies have shown that NAFLD presence predicts the development of type 2 diabetes. Diabetes and NAFLD have mutual pathogenetic mechanisms and it is possible that genetic and environmental factors interact with metabolic derangements to accelerate NAFLD progression in diabetic patients. The diagnosis of the more advanced stages of NAFLD in diabetic patients shares the same challenges as in non-diabetic patients and it includes imaging and serological methods, although histopathological evaluation is still considered the gold standard diagnostic method. An effective established treatment is not yet available for patients with steatohepatitis and fibrosis and randomized clinical trials including only diabetic patients are lacking. We sought to outline the published data including epidemiology, pathogenesis, diagnosis and treatment of NAFLD in diabetic patients, in order to better understand the interplay between these two prevalent diseases and identify the gaps that still need to be fulfilled in the management of NAFLD in patients with diabetes mellitus.
Keywords: Diabetes mellitus; Diagnosis; Non-alcoholic fatty liver disease; Pathogenesis; Treatment.
Figures


Similar articles
-
Non-alcoholic fatty liver disease and type 2 diabetes mellitus: the liver disease of our age?World J Gastroenterol. 2014 Jul 21;20(27):9072-89. doi: 10.3748/wjg.v20.i27.9072. World J Gastroenterol. 2014. PMID: 25083080 Free PMC article. Review.
-
Non-Alcoholic Fatty Liver Disease in Patients with Type 2 Diabetes Mellitus: A Position Statement of the Fatty Liver Research Group of the Korean Diabetes Association.Diabetes Metab J. 2020 Jun;44(3):382-401. doi: 10.4093/dmj.2020.0010. Epub 2020 May 11. Diabetes Metab J. 2020. PMID: 32431115 Free PMC article. Review.
-
Nonalcoholic fatty liver disease, metabolic risk factors, and hepatocellular carcinoma: an open question.World J Gastroenterol. 2015 Apr 14;21(14):4103-10. doi: 10.3748/wjg.v21.i14.4103. World J Gastroenterol. 2015. PMID: 25892859 Free PMC article. Review.
-
Non-Alcoholic Fatty Liver Disease Treatment in Patients with Type 2 Diabetes Mellitus; New Kids on the Block.Curr Vasc Pharmacol. 2020;18(2):172-181. doi: 10.2174/1570161117666190405164313. Curr Vasc Pharmacol. 2020. PMID: 30961499 Review.
-
Cardiovascular risk across the histological spectrum and the clinical manifestations of non-alcoholic fatty liver disease: An update.World J Gastroenterol. 2015 Jun 14;21(22):6820-34. doi: 10.3748/wjg.v21.i22.6820. World J Gastroenterol. 2015. PMID: 26078558 Free PMC article. Review.
Cited by
-
Polyol accumulation in muscle and liver in a mouse model of type 2 diabetes.J Diabetes Complications. 2016 Aug;30(6):999-1007. doi: 10.1016/j.jdiacomp.2016.04.019. Epub 2016 Apr 27. J Diabetes Complications. 2016. PMID: 27197688 Free PMC article.
-
Elevated fasting glucose level increases the risk of fatty liver disease: a 10-year study of 31,154 individuals.BMC Gastroenterol. 2022 Dec 16;22(1):521. doi: 10.1186/s12876-022-02615-0. BMC Gastroenterol. 2022. PMID: 36526962 Free PMC article.
-
Association of MASLD Phenotypes With Liver Fibrosis in Hepatitis C: The Role of Cardiometabolic Risk Factors.J Viral Hepat. 2025 Feb;32(2):e70004. doi: 10.1111/jvh.70004. J Viral Hepat. 2025. PMID: 39868661 Free PMC article.
-
Microbiota, type 2 diabetes and non-alcoholic fatty liver disease: protocol of an observational study.J Transl Med. 2019 Dec 4;17(1):408. doi: 10.1186/s12967-019-02130-z. J Transl Med. 2019. PMID: 31801616 Free PMC article.
-
Endocrinology for the hepatologist.Clin Liver Dis (Hoboken). 2023 May 16;22(1):1-6. doi: 10.1097/CLD.0000000000000037. eCollection 2023 Jul. Clin Liver Dis (Hoboken). 2023. PMID: 37521181 Free PMC article. No abstract available.
References
-
- Younossi ZM, Gramlich T, Matteoni CA, Boparai N, McCullough AJ. Nonalcoholic fatty liver disease in patients with type 2 diabetes. Clin Gastroenterol Hepatol. 2004;2:262–265. - PubMed
-
- Trombetta M, Spiazzi G, Zoppini G, Muggeo M. Review article: type 2 diabetes and chronic liver disease in the Verona diabetes study. Aliment Pharmacol Ther. 2005;22 Suppl 2:24–27. - PubMed
-
- Targher G, Bertolini L, Padovani R, Rodella S, Tessari R, Zenari L, Day C, Arcaro G. Prevalence of nonalcoholic fatty liver disease and its association with cardiovascular disease among type 2 diabetic patients. Diabetes Care. 2007;30:1212–1218. - PubMed
-
- Leite NC, Salles GF, Araujo AL, Villela-Nogueira CA, Cardoso CR. Prevalence and associated factors of non-alcoholic fatty liver disease in patients with type-2 diabetes mellitus. Liver Int. 2009;29:113–119. - PubMed
-
- Prashanth M, Ganesh HK, Vima MV, John M, Bandgar T, Joshi SR, Shah SR, Rathi PM, Joshi AS, Thakkar H, et al. Prevalence of nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus. J Assoc Physicians India. 2009;57:205–210. - PubMed
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical